CN113544278A - 用于逃避体液免疫的组合物和方法 - Google Patents

用于逃避体液免疫的组合物和方法 Download PDF

Info

Publication number
CN113544278A
CN113544278A CN202080019766.8A CN202080019766A CN113544278A CN 113544278 A CN113544278 A CN 113544278A CN 202080019766 A CN202080019766 A CN 202080019766A CN 113544278 A CN113544278 A CN 113544278A
Authority
CN
China
Prior art keywords
antibody
aav
degrading enzyme
protein
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080019766.8A
Other languages
English (en)
Chinese (zh)
Inventor
A·阿索坎
Z·埃尔莫雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of CN113544278A publication Critical patent/CN113544278A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080019766.8A 2019-01-28 2020-01-28 用于逃避体液免疫的组合物和方法 Pending CN113544278A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962797495P 2019-01-28 2019-01-28
US62/797,495 2019-01-28
US201962914682P 2019-10-14 2019-10-14
US62/914,682 2019-10-14
PCT/US2020/015386 WO2020159970A1 (en) 2019-01-28 2020-01-28 Compositions and methods for evading humoral immunity

Publications (1)

Publication Number Publication Date
CN113544278A true CN113544278A (zh) 2021-10-22

Family

ID=71840382

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080019766.8A Pending CN113544278A (zh) 2019-01-28 2020-01-28 用于逃避体液免疫的组合物和方法

Country Status (8)

Country Link
US (1) US20220143213A1 (https=)
EP (1) EP3894571A4 (https=)
JP (1) JP7707066B2 (https=)
KR (1) KR20210126029A (https=)
CN (1) CN113544278A (https=)
AU (1) AU2020215682B2 (https=)
CA (1) CA3127950A1 (https=)
WO (1) WO2020159970A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024066780A1 (zh) * 2022-09-30 2024-04-04 上海玮美基因科技有限责任公司 一种融合型新型腺相关病毒及其应用
CN118497176A (zh) * 2024-07-16 2024-08-16 苏州康聚生物科技有限公司 一种免疫球蛋白降解酶

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021067598A1 (en) 2019-10-04 2021-04-08 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
CA3162020A1 (en) 2019-12-19 2021-06-24 James M. Wilson Compositions for treating friedreich's ataxia
KR20220133969A (ko) 2020-01-28 2022-10-05 프리라인 테라퓨틱스 리미티드 바이러스 벡터에 대한 중화 항체 역가를 결정하기 위한 개선된 분석법
JP2023514204A (ja) 2020-02-14 2023-04-05 ウルトラジェニックス ファーマシューティカル インコーポレイテッド Ｃｄｋｌ５欠損障害を処置するための遺伝子治療
GB202007431D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
EP4274592A4 (en) * 2021-01-11 2025-03-19 The Trustees of The University of Pennsylvania COMPOSITIONS FOR THE TREATMENT OF FRIEDREICH'S ATAXIA
US20250019721A1 (en) 2021-08-11 2025-01-16 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating a muscular dystrophy
WO2025245490A1 (en) * 2024-05-23 2025-11-27 Duke University Compositions comprising antibody cleaving enzymes and methods of use thereof
WO2026041758A1 (en) * 2024-08-22 2026-02-26 Genethon Modified aav capsid with enhanced transduction efficiency

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090317417A1 (en) * 2006-04-28 2009-12-24 The Trustees Of The University Of Pennsylvania Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof
CN107532158A (zh) * 2015-02-12 2018-01-02 汉莎医药有限公司 半胱氨酸蛋白酶

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090317417A1 (en) * 2006-04-28 2009-12-24 The Trustees Of The University Of Pennsylvania Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof
CN107532158A (zh) * 2015-02-12 2018-01-02 汉莎医药有限公司 半胱氨酸蛋白酶

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"IgG-degrading enzyme/Mac-1 IdeZ [Streptococcus equi]", GENBANK DATABASE, 17 May 2013 (2013-05-17) *
LONGPING V TSE ET AL.: "Strategies to circumvent humoral immunity to adeno-associated viral vectors", EXPERT OPIN BIOL THER, vol. 15, no. 6, 30 June 2015 (2015-06-30), pages 2, XP055763945, DOI: 10.1517/14712598.2015.1035645 *
LONGPING V TSE ET AL.: "Strategies to circumvent humoral immunity to adeno-associated viral vectors", EXPERT OPIN BIOL THER, vol. 15, no. 6, pages 2 *
NANDAKUMAR, K.S. AND HOLMDAHL, R.: "Therapeutic cleavage of IgG: new avenues for treating inflammation", TRENDS IMMUNOL, vol. 29, no. 4, 30 April 2008 (2008-04-30), pages 174 *
NANDAKUMAR, K.S. AND HOLMDAHL, R.: "Therapeutic cleavage of IgG: new avenues for treating inflammation", TRENDS IMMUNOL, vol. 29, no. 4, pages 174 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024066780A1 (zh) * 2022-09-30 2024-04-04 上海玮美基因科技有限责任公司 一种融合型新型腺相关病毒及其应用
CN118497176A (zh) * 2024-07-16 2024-08-16 苏州康聚生物科技有限公司 一种免疫球蛋白降解酶

Also Published As

Publication number Publication date
CA3127950A1 (en) 2020-08-06
JP2022523679A (ja) 2022-04-26
EP3894571A1 (en) 2021-10-20
US20220143213A1 (en) 2022-05-12
AU2020215682A1 (en) 2021-08-19
AU2020215682B2 (en) 2025-12-18
EP3894571A4 (en) 2022-09-14
JP7707066B2 (ja) 2025-07-14
WO2020159970A1 (en) 2020-08-06
KR20210126029A (ko) 2021-10-19

Similar Documents

Publication Publication Date Title
CN113544278A (zh) 用于逃避体液免疫的组合物和方法
JP7390693B2 (ja) 抗体回避性ウイルスベクターのための方法および組成物
M Mitchell et al. AAV's anatomy: roadmap for optimizing vectors for translational success
EP4303225A2 (en) Polyploid adeno-associated virus vectors and methods of making and using the same
JP7756439B2 (ja) 異種間適合性アデノ随伴ウイルス組成物およびその使用方法
JP2021516044A (ja) 抗体回避ウイルスベクターのための方法および組成物
JP2022523679A5 (https=)
CN115960921A (zh) 一组肝靶向新型腺相关病毒的获得及其应用
JP2024506266A (ja) 遺伝性血管性浮腫を治療するための組成物および方法
AU2021320419A1 (en) Vesicle targeting proteins and uses of same
KR20230152008A (ko) 단백질 m 유사체 및 융합 단백질 및 이들의 항체 기능 억제 용도
US20230013145A1 (en) Aav capsid-promoter interactions and cell selective gene expression
WO2023012313A1 (en) Hybrid promoters for gene expression in muscles and in the cns
HK40061172A (en) Compositions and methods for evading humoral immunity
WO2019191716A1 (en) Aav6 variants
TW202400796A (zh) 雙向雙重啟動子表現載體及其用途
WO2024105638A1 (en) Recombinant aav vectors and methods for treatment of hunter syndrome
KR20260057459A (ko) 약학적 조성물 및 이의 용도
HK40098885A (en) Polyploid adeno-associated virus vectors and methods of making and using the same
CN117120076A (zh) 用于治疗遗传性血管性水肿的组合物和方法
Johnson 749. Adeno-Associated Virus Vectors Integrate at Chromosome Breakage Sites
Kuo et al. 751. Breaking Down AAV: Defining the Minimal Capsid Sequences for AAV Function

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40061172

Country of ref document: HK